| name | counseling-smoking-cessation |
| description | Structures 5As smoking cessation intervention with pharmacotherapy selection and motivational interviewing. Use when counseling on tobacco use, prescribing cessation aids, or documenting quit attempts. |
| tags | ["counseling","primary-care"] |
| metadata | {"author":"casemark","practice_areas":["Family Medicine","Internal Medicine","Primary Care"],"document_types":["Counseling Note"],"skill_modes":["Counseling"]} |
Counseling Smoking Cessation
Structures 5As smoking cessation intervention with pharmacotherapy selection and motivational interviewing.
Why This Skill Exists
Tobacco use remains the leading preventable cause of death in the United States, killing approximately 480,000 Americans annually. Smoking increases the risk of lung cancer by 15-30x, COPD by 10x, and coronary heart disease by 2-4x. The USPSTF gives an "A" recommendation for asking all adults about tobacco use and providing cessation interventions to those who use tobacco. Despite this, only 57% of smokers receive cessation advice at medical visits, and fewer than 5% receive pharmacotherapy, despite medications tripling quit rates.
The 5As framework (Ask, Advise, Assess, Assist, Arrange) and the 5Rs (for those not ready to quit) provide the evidence-based structure for brief counseling interventions. Combined with FDA-approved pharmacotherapy, these interventions represent the single most cost-effective preventive service in medicine, with a cost per quality-adjusted life year (QALY) of $1,000-$5,000—far below accepted thresholds. This skill ensures every tobacco-using patient receives a guideline-concordant cessation intervention at every visit.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What form of tobacco does the patient use (cigarettes, cigars, pipe, chew, vape/e-cigarettes)? Default: cigarettes
- How many cigarettes per day and for how many years (calculate pack-years)? Default: [REQUIRED]
- Has the patient attempted to quit before? How many times and what methods? Default: unknown
- Is the patient currently ready to make a quit attempt (pre-contemplation, contemplation, preparation, action)? Default: assess
- What is the Fagerstrom Test for Nicotine Dependence (FTND) score? Default: administer
- Does the patient have comorbidities affecting pharmacotherapy choice (seizure disorder, eating disorder, MI within 2 weeks, pregnancy)? Default: per history
- Is the patient eligible for lung cancer screening (age 50-80, ≥20 pack-years, current or quit <15 years)? Default: assess
- Does the patient have behavioral health comorbidities (depression, anxiety, substance use disorder)? Default: per history
Documents to Request
- Tobacco use history with pack-year calculation
- Prior quit attempt records (methods used, duration of abstinence, relapse triggers)
- Fagerstrom Test for Nicotine Dependence (FTND) questionnaire
- Current medication list (potential interactions with cessation meds)
- PHQ-9 and AUDIT-C (depression and alcohol screening—both affect quit success)
- Lung cancer screening eligibility assessment
- Insurance formulary for cessation medication coverage
- Quitline referral status (1-800-QUIT-NOW)
Step 1: The 5As Framework
ASK — Screen every patient at every visit:
- "Do you currently use tobacco in any form (cigarettes, e-cigarettes, cigars, smokeless, hookah)?"
- Document status: current user, former user (quit date), never user
- Update tobacco use vital sign at every encounter
ADVISE — Provide clear, strong, personalized advice:
- "As your doctor, I want you to know that quitting tobacco is the single most important thing you can do for your health."
- Personalize: link to patient's specific conditions (e.g., "Quitting will significantly reduce your risk of another heart attack")
- Duration: 30-60 seconds is sufficient for the advise step
- Be non-judgmental and empathetic
ASSESS — Determine readiness to quit:
- "Are you willing to make a quit attempt in the next 30 days?"
- If YES → proceed to ASSIST
- If NO → apply the 5Rs (see Step 2)
- If recently quit → provide relapse prevention support
ASSIST — Help the patient quit:
- Set a quit date (ideally within 2 weeks)
- Recommend combination therapy: counseling + pharmacotherapy (see Steps 3-4)
- Refer to tobacco quitline: 1-800-QUIT-NOW (free, all states)
- Identify triggers and develop coping strategies
- Advise removing tobacco products, lighters, and ashtrays from home, car, and workplace
- Inform household members for support
ARRANGE — Schedule follow-up:
- Follow-up call or visit within 1 week of quit date
- Second follow-up within 1 month
- Ongoing support at subsequent visits
- Congratulate any progress; do not criticize relapse
Step 2: The 5Rs (For Patients Not Ready to Quit)
| R | Description | Example |
|---|
| Relevance | Make it personal to their health, family, concerns | "Your COPD will continue to worsen if you keep smoking" |
| Risks | Discuss acute, long-term, and environmental risks | "Secondhand smoke increases your children's asthma attacks" |
| Rewards | Highlight personal benefits of quitting | "You'll save approximately $3,000/year; food will taste better; shortness of breath will improve" |
| Roadblocks | Identify barriers | "What makes quitting hardest for you?" (weight gain, stress, withdrawal, social smoking) |
| Repetition | Repeat at every visit | Motivation fluctuates; patients who aren't ready today may be ready next visit |
Document the motivational intervention and the patient's stage of change. Even a 30-second intervention increases quit rates.
Step 3: FDA-Approved Pharmacotherapy
All FDA-approved cessation medications approximately double quit rates (from ~7% to ~15% at 6 months); combination therapy can triple rates.
| Agent | Dosing | Duration | Key Considerations |
|---|
| Nicotine patch (OTC) | 21mg/day (>10 cigs/day) × 6 wks; 14mg × 2 wks; 7mg × 2 wks | 8-12 weeks | Start on quit date; can use with short-acting NRT |
| Nicotine gum (OTC) | 2mg (first cigarette >30 min after waking); 4mg (first cigarette ≤30 min) | Up to 12 weeks | Chew-and-park technique; avoid acidic beverages |
| Nicotine lozenge (OTC) | 2mg or 4mg (same criteria as gum) | Up to 12 weeks | Dissolve in mouth; do not chew or swallow |
| Nicotine inhaler (Rx) | 6-16 cartridges/day | Up to 6 months | Mimics hand-to-mouth behavior |
| Nicotine nasal spray (Rx) | 1-2 sprays per nostril q1h; max 40 sprays/day | 3-6 months | Fastest nicotine delivery of NRT products |
| Varenicline (Chantix) (Rx) | 0.5mg daily × 3 days; 0.5mg BID × 4 days; 1mg BID thereafter | 12 weeks (extend to 24 for higher quit rates) | Most effective single agent; start 1 week before quit date; nausea most common SE |
| Bupropion SR (Zyban) (Rx) | 150mg daily × 3 days; then 150mg BID | 7-12 weeks (can extend to 6 months) | Start 1-2 weeks before quit date; contraindicated in seizure disorder, eating disorder |
Preferred combinations:
- Nicotine patch + nicotine gum/lozenge (patch for baseline; gum/lozenge for cravings)
- Varenicline alone (highest single-agent efficacy per EAGLES trial)
- Varenicline + nicotine patch (emerging evidence of superior efficacy)
Step 4: Special Populations
| Population | Considerations |
|---|
| Pregnancy | NRT (patch, gum) preferred if behavioral interventions insufficient; varenicline and bupropion not FDA-approved in pregnancy; benefits of cessation outweigh NRT risks |
| Cardiovascular disease | All cessation medications are safe including in recent ACS (per 2018 Cochrane review); benefit of quitting far outweighs medication risk |
| Psychiatric illness | EAGLES trial: no increased neuropsychiatric events with varenicline or bupropion vs. placebo in psychiatric patients; black box warning removed by FDA in 2016 |
| Adolescents (<18) | Behavioral counseling first-line; NRT may be considered if nicotine-dependent; limited evidence for varenicline/bupropion |
| E-cigarette / vape users | No FDA-approved cessation pharmacotherapy for e-cigarette use specifically; apply behavioral strategies; dual users should quit both |
| Light/intermittent smokers | Behavioral counseling primary; NRT gum/lozenge PRN for cravings; patch may cause excess nicotine if <10 cigs/day |
Step 5: Relapse Prevention and Long-Term Management
- 70-80% of quit attempts end in relapse, most within the first 3 months
- Identify and plan for high-risk situations: alcohol use, social events, stress, weight gain, boredom
- Weight gain averages 4-5 kg in the first year; counsel proactively; increased exercise mitigates
- If relapse occurs: frame as a learning opportunity, not a failure; assess triggers, reinforce motivation, restart pharmacotherapy
- Document smoking status at every visit for at least 2 years post-quit
- After 12 months abstinent: former smoker status, annual reassessment, LDCT screening if eligible
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is tobacco use status documented at the current visit (current, former, never)?
- Has the 5As framework been applied with documentation of each step?
- Has pharmacotherapy been offered to every patient willing to quit?
- Is the quit date set and follow-up scheduled within 1 week?
- Has lung cancer screening eligibility been assessed for patients ≥50 with ≥20 pack-years?
Quality Audit
Guidelines
- Every tobacco-using patient should be offered cessation intervention at every visit—even a 30-second motivational message increases quit rates by 1-3%
- Pharmacotherapy should be offered to ALL patients willing to quit; the "willpower only" approach has the lowest success rate (<5%)
- Varenicline is the most effective single-agent cessation medication (OR 2.24 vs. placebo per Cochrane 2016); it does NOT carry a black box warning for neuropsychiatric events as of 2016
- Combination NRT (patch + short-acting NRT) is more effective than any single NRT product alone
- Bupropion is CONTRAINDICATED in seizure disorders, active eating disorders (anorexia/bulimia), and concurrent use of MAOIs
- E-cigarettes are NOT FDA-approved cessation aids; do not recommend e-cigarettes as a primary cessation strategy, though acknowledge reduced harm in patients who switch completely from combustible tobacco
- Nicotine replacement therapy is safe in cardiovascular disease; the misconception that NRT is dangerous after MI was disproven by multiple studies
- Document tobacco use and cessation interventions to support MIPS quality measure #226 (Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention)
